BR0209133A - Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangue - Google Patents
Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangueInfo
- Publication number
- BR0209133A BR0209133A BR0209133-0A BR0209133A BR0209133A BR 0209133 A BR0209133 A BR 0209133A BR 0209133 A BR0209133 A BR 0209133A BR 0209133 A BR0209133 A BR 0209133A
- Authority
- BR
- Brazil
- Prior art keywords
- uric acid
- polymer
- patient
- acid levels
- reduce blood
- Prior art date
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title abstract 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title abstract 4
- 229940116269 uric acid Drugs 0.000 title abstract 4
- 201000005569 Gout Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 229920000642 polymer Polymers 0.000 abstract 6
- 150000001412 amines Chemical class 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 abstract 1
- 229920002905 Colesevelam Polymers 0.000 abstract 1
- KHNXRSIBRKBJDI-UHFFFAOYSA-N Sevelamer hydrochloride Chemical compound Cl.NCC=C.ClCC1CO1 KHNXRSIBRKBJDI-UHFFFAOYSA-N 0.000 abstract 1
- 229960001152 colesevelam Drugs 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 229920006037 cross link polymer Polymers 0.000 abstract 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960003027 sevelamer hydrochloride Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Dental Preparations (AREA)
- Adhesives Or Adhesive Processes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28444501P | 2001-04-18 | 2001-04-18 | |
| US30556701P | 2001-07-13 | 2001-07-13 | |
| PCT/US2002/011492 WO2002085381A1 (en) | 2001-04-18 | 2002-04-10 | Method for treating gout and binding uric acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0209133A true BR0209133A (pt) | 2004-06-15 |
Family
ID=26962624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0209133-0A BR0209133A (pt) | 2001-04-18 | 2002-04-10 | Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangue |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20030039627A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1416942B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2004528332A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE380553T1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0209133A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2444347A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60224052T2 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA03009571A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002085381A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| WO2004037274A1 (en) * | 2002-10-22 | 2004-05-06 | Genzyme Corporation | Amine polymers for promoting bone formation |
| WO2004099288A1 (en) * | 2003-05-09 | 2004-11-18 | Carlsberg A/S | Polyethyleneimine polymers |
| US7335795B2 (en) | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7385012B2 (en) | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| US7449605B2 (en) * | 2003-11-03 | 2008-11-11 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7767768B2 (en) * | 2003-11-03 | 2010-08-03 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7608674B2 (en) | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
| US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
| WO2006072054A1 (en) * | 2004-12-30 | 2006-07-06 | Genzyme Corporation | Zinc-containing treatments for hyperphosphatemia |
| WO2006121995A2 (en) * | 2005-05-09 | 2006-11-16 | Tap Pharmaceutical Products, Inc. | Methods for treating nephrolithiasis |
| JP2009507019A (ja) * | 2005-09-02 | 2009-02-19 | ジェンザイム・コーポレーション | リン酸塩を除去する方法およびそれに使用される重合体 |
| DK1924246T3 (en) | 2005-09-15 | 2016-01-18 | Genzyme Corp | PORTION LETTER DEFINITION OF amine polymers |
| BRPI0618352A2 (pt) * | 2005-11-08 | 2011-08-23 | Genzyme Corp | composições farmacêuticas e métodos de tratamento da hiperfosfatemia em um paciente |
| EP2016114A2 (en) * | 2006-05-05 | 2009-01-21 | Genzyme Corporation | Amine condensation polymers as phosphate sequestrants |
| US20100135950A1 (en) * | 2006-07-05 | 2010-06-03 | Genzyme Corporation | Iron(II)-Containing Treatments for Hyperphosphatemia |
| US20100124542A1 (en) * | 2006-07-18 | 2010-05-20 | Genzyme Corporation | Amine dendrimers |
| BRPI0717545A2 (pt) | 2006-09-29 | 2013-10-22 | Gezyme Corp | Composição farmacêutica, método para tratar uma doença, polímero de amida, rede de polímero, e, método para preparar um polímero de amida |
| US20090124623A1 (en) * | 2006-11-13 | 2009-05-14 | Christopher Lademacher | Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors |
| WO2008064015A1 (en) * | 2006-11-13 | 2008-05-29 | Takeda Pharmaceuticals North America | Methods for preserving renal function using xanthine oxidoreductase inhibitors |
| BRPI0720234A2 (pt) * | 2006-12-14 | 2013-12-24 | Genzyme Corp | Composição farmacêutica |
| RU2009131454A (ru) * | 2007-01-19 | 2011-02-27 | Такеда Фармасьютикалз Норт Америка, Инк. (Us) | Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств |
| JP2010519298A (ja) * | 2007-02-23 | 2010-06-03 | ゲンズイメ コーポレーション | アミンポリマー組成物 |
| US20100196305A1 (en) * | 2007-03-08 | 2010-08-05 | Dhal Pradeep K | Sulfone polymer compositions |
| EP2152277A1 (en) * | 2007-04-27 | 2010-02-17 | Genzyme Corporation | Amido-amine dendrimer compositions |
| EP2217215A1 (en) * | 2007-12-14 | 2010-08-18 | Genzyme Corporation | Coated pharmaceutical compositions |
| WO2009154747A1 (en) * | 2008-06-20 | 2009-12-23 | Genzyme Corporation | Pharmaceutical compositions |
| US20100311756A1 (en) * | 2009-01-22 | 2010-12-09 | Takeda Pharmaceuticals North America, Inc. | Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof |
| KR101797936B1 (ko) | 2010-09-10 | 2017-11-15 | 다케다 파마슈티칼스 유에스에이, 인코포레이티드 | 테오필린과 페북소스타트의 병용 치료 방법 |
| KR20210131457A (ko) | 2013-06-05 | 2021-11-02 | 트리시다, 인크. | 경구 투여를 위한 양성자-결합 중합체 |
| ES2787218T3 (es) | 2014-12-10 | 2020-10-15 | Tricida Inc | Polímeros de unión de protones para la administración oral |
| EP3452028A4 (en) | 2016-05-06 | 2020-04-15 | Tricida Inc. | COMPOSITIONS AND METHOD FOR TREATING ACID-BASED DISORDERS |
| BR112019013364A2 (pt) | 2016-12-28 | 2020-04-14 | Fujifilm Corp | emulsão de polímero contendo átomo de nitrogênio ou sal do mesmo, método de produção para o mesmo e método de produção para partículas |
| EP3698799B1 (en) | 2017-10-16 | 2022-01-26 | FUJIFILM Corporation | Hyperphosphatemia treatment agent |
| SG11202003451UA (en) | 2017-11-03 | 2020-05-28 | Tricida Inc | Compositions for and method of treating acid-base disorders |
| ES2995007T3 (en) * | 2021-08-24 | 2025-02-05 | Waterstone Pharmaceuticals Wuhan Co Ltd | Polymers, compositions and methods for treating hyperuricemia |
| EP4164659B1 (en) * | 2021-08-24 | 2024-03-27 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Polymers, compositions and methods for treating hyperuricemia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4271191A (en) * | 1979-12-19 | 1981-06-02 | Pierre Fabre S.A. | Method of treating hyperuricemia and gout |
| DE3727082A1 (de) * | 1987-08-14 | 1989-02-23 | Goedecke Ag | Pharmazeutische zubereitungen zur behandlung der urolithiasis |
| JP4358303B2 (ja) * | 1996-10-23 | 2009-11-04 | ダウ グローバル テクノロジーズ インコーポレイティド | 食物ホスフェート又はオキサレート吸収を低下させるための水溶性ポリマー |
| US5985938A (en) * | 1997-11-05 | 1999-11-16 | Geltex Pharmaceuticals, Inc. | Method for reducing oxalate |
| WO2002085380A1 (en) * | 2001-04-18 | 2002-10-31 | Geltex Pharmaceuticals, Inc. | Method for treating gout and reducing serum uric acid |
-
2002
- 2002-04-10 MX MXPA03009571A patent/MXPA03009571A/es unknown
- 2002-04-10 JP JP2002582954A patent/JP2004528332A/ja active Pending
- 2002-04-10 EP EP02726732A patent/EP1416942B1/en not_active Expired - Lifetime
- 2002-04-10 CA CA002444347A patent/CA2444347A1/en not_active Abandoned
- 2002-04-10 AT AT02726732T patent/ATE380553T1/de not_active IP Right Cessation
- 2002-04-10 DE DE60224052T patent/DE60224052T2/de not_active Expired - Lifetime
- 2002-04-10 WO PCT/US2002/011492 patent/WO2002085381A1/en not_active Ceased
- 2002-04-10 BR BR0209133-0A patent/BR0209133A/pt not_active IP Right Cessation
- 2002-04-17 US US10/125,685 patent/US20030039627A1/en not_active Abandoned
-
2007
- 2007-06-18 US US11/820,292 patent/US20080112918A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1416942B1 (en) | 2007-12-12 |
| DE60224052D1 (de) | 2008-01-24 |
| WO2002085381A1 (en) | 2002-10-31 |
| JP2004528332A (ja) | 2004-09-16 |
| ATE380553T1 (de) | 2007-12-15 |
| CA2444347A1 (en) | 2002-10-31 |
| MXPA03009571A (es) | 2004-02-12 |
| US20030039627A1 (en) | 2003-02-27 |
| EP1416942A1 (en) | 2004-05-12 |
| DE60224052T2 (de) | 2008-11-06 |
| US20080112918A1 (en) | 2008-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0209133A (pt) | Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangue | |
| CY1119486T1 (el) | Χρηση πολυμερους αμινης για μειωση της γλυκοζης στον ορο | |
| MY125874A (en) | Use of polyallylamine polymers for the manufacture of a medicament for treating hypercholesterolemia | |
| CA2349620A1 (en) | Use of aliphatic polyamines for reducing oxalate | |
| RU2010104673A (ru) | Сшитый полиаллиламин или его соль присоединения кислоты и его применение для медицинских целей | |
| MA29678B1 (fr) | Nouvelle methode de prevention ou de traitement d'une infection par m tuberculosis | |
| BRPI0512213A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
| BR0009486A (pt) | Compostos que contêm uma amida, utilização desses compostos, composição farmacêutica, processo para o tratamento profilático ou terapêutico de, diabetes do tipo ii e processo para a preparação dos compostos | |
| DK1385898T3 (da) | Farmaceutisk sammensætning omfattende poly(alkylenoxider) med reducerede mængder af myresyreforbindelser | |
| WO2000040235A3 (en) | Treatment of asthma with mek inhibitors | |
| BRPI0306993B8 (pt) | polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível | |
| MEP28208A (en) | Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure | |
| BR0212907A (pt) | Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis | |
| CY1107640T1 (el) | Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη | |
| ATE496048T1 (de) | Phenylcarboxamidverbindungen zur schmerzbehandlung | |
| CY1108377T1 (el) | Χρηση ενωσεων 1-φαινυλο-3-διμεθυλαμινο-προπανιου για τη θεραπεια της ακρατειας ουρων | |
| EA200300882A1 (ru) | Способ лечения демиелинизирующих заболеваний или состояний | |
| RU2008108516A (ru) | 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИН ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНОГО ЗАБОЛЕВАНИЯ ИЛИ ВОСПАЛЕНИЯ | |
| EA201000630A1 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови | |
| BR9813372A (pt) | ElastÈmeros de poliuretano e de poliuretano/uréia curados por calor e curados por umidade com propriedades fìsicas aperfeiçoadas | |
| WO2007056405A3 (en) | Magnesium-containing polymers for the treatment of hyperphosphatemia | |
| CA2508282A1 (en) | Compositions comprising n-isopropylacrylamide and methods for inhibiting protein adsorption on surfaces | |
| BRPI0413684A (pt) | compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos | |
| EP1923064A3 (en) | Use of amine polymer for lowering serum glucose | |
| BR9907234A (pt) | Polìmeros ligantes de gordura |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A(S) 8A E 9A ANUIDADE(S) |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011. |